ArticlePloS one2025
Evaluation of organotin (IV) dithiocarbamate compounds as potential anti-leukemia agents towards CCRF-CEM (CCL-119) cell line: Cytotoxic, apoptotic, cell cycle and genotoxic study.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute lymphoblastic leukemia (ALL) is a common cancer affecting children worldwide, and current treatment has adverse effects such as neurotoxicity. To overcome this problem, new organotin (IV) dithiocarbamate compounds were synthesized. In this study, the T-lymphoblastic leukemia cell line (CCL-119) was tested against seven new compounds: diphenyltin (IV) diisopropyl dithiocarbamate (ODTC 1), diphenyltin (IV) diallyl dithiocarbamate (ODTC 2), triphenyltin (IV) diisopropyl dithiocarbamate (ODTC 3), triphenyltin (IV) diallyl dithiocarbamate (ODTC 4), triphenyltin (IV) diethyl dithiocarbamate (ODTC 5), dimethyltin (IV) diisopropyl dithiocarbamate (ODTC 6) and dimethyltin (IV) diethyl dithiocarbamate (ODTC 7) hereafter referred to as ODTC 1-7, to identify their cytotoxic effects (MTT assay), mode of cell death (Annexin V FITC/PI staining) and effects on the cell cycle (RNase/PI staining) as well as genotoxic effects (alkaline comet assay). Results obtained after 24 hours of exposure showed that all organotin (IV) dithiocarbamate compounds (ODTC 1-7) exhibited potent cytotoxicity, with median inhibitory concentration (IC50) values ranging from 0.18 µM to 3.10 µM. The selectivity index showed that diphenyltin (IV) and triphenyltin (IV) dithiocarbamate compounds are more selective towards CCL-119 cells. All ODTC compounds induced apoptosis in CCL-119 cells, and each compound caused cell cycle arrest at specific phases, indicating diverse mechanisms of action. Apoptosis and cell cycle arrest were confirmed by flow cytometry. Treatment of the compounds caused significant (p < 0.05) DNA damage compared to the negative control, with ODTC 1 causing the highest genotoxic effects. In conclusion, diphenyltin (IV) and triphenyltin (IV) dithiocarbamate compounds show good potential as anti-leukemia agents. However, further studies on the mechanisms of action need to be conducted to have better insights into the effect of this compound on CCL-119 leukemia cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.